BC Innovations | Sep 27, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Viral hemorrhagic fever Non-human primates studies suggest mAbs against Lassa virus glycoprotein could help prevent or treat Lassa fever. In a cynomolgus macaque lethal Lassa virus challenge model, each of five human mAbs against...
BC Extra | Sep 6, 2017
Preclinical News

Human mAbs could treat Lassa fever

In a paper published in Nature Medicine , researchers at the University of Texas , Tulane University and Zalgen Labs LLC (Germantown, Md.) showed that Lassa virus glycoprotein-neutralizing mAbs rescued non-human primates infected with Lassa virus, suggesting...
BC Week In Review | Sep 5, 2016
Company News

Corgenix Medical Corp., Zalgen Labs deal

Zalgen purchased Corgenix’s viral hemorrhagic fever diagnostics business. The business includes the ReEBOV Antigen Rapid Test to detect the Ebola virus and the ReLASV Antigen Rapid Test to diagnose Lassa fever. Concurrent with the acquisition,...
BC Innovations | Jan 15, 2015
Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
BC Innovations | May 29, 2014
Strategy

New York's biotech beginnings

New York has long produced top science but has struggled to retain and develop its own innovations. The city says it hopes a flurry of public-private partnerships, real estate developments and high-profile academic appointments will...
BC Innovations | Apr 17, 2014
Translation in Brief

Translational tidbits

AstraZeneca plc had a busy March, announcing five new public-private partnerships and the launch of its Open Innovation website to list additional partnership opportunities ( see "Selected public-private partnerships for March 2014"). One of the public-private...
BC Week In Review | Mar 31, 2014
Company News

Emergent BioSolutions, Mapp Biopharmaceutical, Zalgen Labs, Ben-Gurion University of the Negev, NIH, Public Health Agency of Canada, Scripps Research Institute,

NIH's National Institute of Allergy and Infectious Disease (NIAID) awarded a consortium led by Scripps a five-year grant worth up to $28 million to develop immunotherapies for filoviruses and arenaviruses that cause severe hemorrhagic fever,...
BC Week In Review | Nov 25, 2013
Company News

Corgenix Medical Corp., Zalgen Labs deal

The companies partnered to develop a next-generation rapid test kit for the early detection of active cytomegalovirus (CMV) infections and previous exposure to the virus in women of childbearing age. The partners will initially collaborate...
Items per page:
1 - 8 of 8
BC Innovations | Sep 27, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Viral hemorrhagic fever Non-human primates studies suggest mAbs against Lassa virus glycoprotein could help prevent or treat Lassa fever. In a cynomolgus macaque lethal Lassa virus challenge model, each of five human mAbs against...
BC Extra | Sep 6, 2017
Preclinical News

Human mAbs could treat Lassa fever

In a paper published in Nature Medicine , researchers at the University of Texas , Tulane University and Zalgen Labs LLC (Germantown, Md.) showed that Lassa virus glycoprotein-neutralizing mAbs rescued non-human primates infected with Lassa virus, suggesting...
BC Week In Review | Sep 5, 2016
Company News

Corgenix Medical Corp., Zalgen Labs deal

Zalgen purchased Corgenix’s viral hemorrhagic fever diagnostics business. The business includes the ReEBOV Antigen Rapid Test to detect the Ebola virus and the ReLASV Antigen Rapid Test to diagnose Lassa fever. Concurrent with the acquisition,...
BC Innovations | Jan 15, 2015
Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
BC Innovations | May 29, 2014
Strategy

New York's biotech beginnings

New York has long produced top science but has struggled to retain and develop its own innovations. The city says it hopes a flurry of public-private partnerships, real estate developments and high-profile academic appointments will...
BC Innovations | Apr 17, 2014
Translation in Brief

Translational tidbits

AstraZeneca plc had a busy March, announcing five new public-private partnerships and the launch of its Open Innovation website to list additional partnership opportunities ( see "Selected public-private partnerships for March 2014"). One of the public-private...
BC Week In Review | Mar 31, 2014
Company News

Emergent BioSolutions, Mapp Biopharmaceutical, Zalgen Labs, Ben-Gurion University of the Negev, NIH, Public Health Agency of Canada, Scripps Research Institute,

NIH's National Institute of Allergy and Infectious Disease (NIAID) awarded a consortium led by Scripps a five-year grant worth up to $28 million to develop immunotherapies for filoviruses and arenaviruses that cause severe hemorrhagic fever,...
BC Week In Review | Nov 25, 2013
Company News

Corgenix Medical Corp., Zalgen Labs deal

The companies partnered to develop a next-generation rapid test kit for the early detection of active cytomegalovirus (CMV) infections and previous exposure to the virus in women of childbearing age. The partners will initially collaborate...
Items per page:
1 - 8 of 8